| | | | | Breakthrough | | |
|--------------|----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|--------------|----------|--------------------------------------|
| | | | | therapy | Priority | Date and price of acquisition if the |
| Manufacturer | | | Estimated volume of patients | designation? | Review? | drug was not developed by the |
| Name | NDC Name of Prescription Drug | A description of the marketing and pricing plans used in the launch of the new drug | who may be prescribed drug | (Y/N) | (Y/N) | manufacturer else N/A |
| | | | | | | |
| | | Marketing initiatives are expected to include print and digital media, engagement at scientific | | | | |
| | | meetings attended by Healthcare Providers (HCPs) most likely to manage patients with cystic | | | | |
| | | fibrosis, materials to be used by sales representatives to share information on Bronchitol with | | | | |
| | | HCPs who treat patients with cystic fibrosis or prescribe Bronchitol to such patients, and | | | | |
| | | materials to educate patients about cystic fibrosis and Bronchitol. Sustainability has always | | | | |
| | | been important for Chiesi, but today it is part of our strategic plan. This means that we are | | | | |
| | | committed to improving the quality of life of patients, to protect the planet and its inhabitants, | | | | |
| | | to put ourselves at the service of the community, to encourage the growth of our people, and to | | | | |
| Chiesi USA | 10122021256 Bronchitol 4-Week Carton (56ct carton) | guarantee the maximum transparency of our work. | 622 | N | N | N/A |
| | | | | | | |
| | | Marketing initiatives are expected to include print and digital media, engagement at scientific | | | | |
| | | meetings attended by Healthcare Providers (HCPs) most likely to manage patients with cystic | | | | |
| | | fibrosis, materials to be used by sales representatives to share information on Bronchitol with | | | | |
| | | HCPs who treat patients with cystic fibrosis or prescribe Bronchitol to such patients, and | | | | |
| | | materials to educate patients about cystic fibrosis and Bronchitol. Sustainability has always | | | | |
| | | been important for Chiesi, but today it is part of our strategic plan. This means that we are | | | | |
| | | committed to improving the quality of life of patients, to protect the planet and its inhabitants, | | | | |
| Chinni HCA | 10122021201 Burn shits I Talanan a Tart | to put ourselves at the service of the community, to encourage the growth of our people, and to guarantee the maximum transparency of our work. | 622 | | N | N/A |
| Chiesi USA | 10122021204 Bronchitol Tolerance Test | guarantee the maximum transparency of our work. | 622 | N | IN | N/A |
| | | Marketing initiatives are expected to include print and digital media, engagement at scientific | | | | |
| | | meetings attended by Healthcare Providers (HCPs) most likely to manage patients with cystic | | | | |
| | | fibrosis, materials to be used by sales representatives to share information on Bronchitol with | | | | |
| | | HCPs who treat patients with cystic fibrosis or prescribe Bronchitol to such patients, and | | | | |
| | | materials to educate patients about cystic fibrosis and Bronchitol. Sustainability has always | | | | |
| | | been important for Chiesi, but today it is part of our strategic plan. This means that we are | | | | |
| | | committed to improving the quality of life of patients, to protect the planet and its inhabitants, | | | | |
| | | to put ourselves at the service of the community, to encourage the growth of our people, and to | | | | |
| Chiesi USA | 10122021214 Bronchitol 7-Day Carton (14ct carton) | guarantee the maximum transparency of our work. | 622 | N | N | N/A |
| | | lo | | · · · · · · | | , ., |